MedTrace Logo

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

NCT00889382 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2024-11-20

No results posted yet for this study

Summary

This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.

Conditions

Interventions

DRUG

OSI-906

Administered orally

DRUG

Paclitaxel

Administered intravenously

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Principal Investigator - Czech Republic · General Faculty Hospital, Charles University

  • Medical Director · Astellas Pharma Global Development

  • Principal Investigator - Italy · Instituto Europeo de Oncologia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-05
Primary Completion
2014-08-01
Completion
2014-08-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Italy
  • Poland
  • Romania
  • Russia
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00889382 on ClinicalTrials.gov